Immutep (IMMP) Intangibles (2011 - 2025)
Immutep's (IMMP) quarterly Intangibles came in at $3.9 million in Q4 2025, down 23.12% YoY from $5.1 million in Q4 2024, and down 15.21% on a QoQ basis from $4.6 million in Q2 2025.
Immutep (IMMP) Intangibles (2011 - 2025) Analysis & Trends
Immutep (IMMP) has 15 years of Intangibles data on file, last reported at $3.9 million in Q4 2025.
- Quarterly Intangibles fell 23.12% year-over-year to $3.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $3.9 million (down 23.12% YoY) and the FY2025 annual result came in at $4.6 million, down 15.09% from the prior year.
- Intangibles declined to $3.9 million in Q4 2025, from $4.6 million in the prior quarter.
- In the past five years, Intangibles ranged from a high of $9.9 million in Q2 2021 to a low of $3.9 million in Q4 2025.
- A 5-year average of $6.4 million and a median of $6.0 million in 2023 frame the typical range for Intangibles.
- Annual changes were most pronounced in 2021 — Intangibles slipped 0.66% — and 2022, when it fell 23.59%.
- Tracing IMMP's Intangibles over 5 years: stood at $8.6 million in 2021, then declined by 23.19% to $6.6 million in 2022, then retreated by 13.45% to $5.7 million in 2023, then declined by 10.62% to $5.1 million in 2024, then decreased by 23.12% to $3.9 million in 2025.
- The last three Intangibles figures came in at $3.9 million (Q4 2025), $4.6 million (Q2 2025), and $5.1 million (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 412.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.31 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 266.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 60.96 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 93.49 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Immutep | 56.46 Mn | -8.63 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 3.91 Mn |
| Jun 30, 2025 | 4.61 Mn |
| Dec 31, 2024 | 5.09 Mn |
| Jun 30, 2024 | 5.43 Mn |
| Dec 31, 2023 | 5.69 Mn |
| Jun 30, 2023 | 6.34 Mn |
| Dec 31, 2022 | 6.57 Mn |
| Jun 30, 2022 | 7.56 Mn |
| Dec 31, 2021 | 8.56 Mn |
| Jun 30, 2021 | 9.89 Mn |
| Dec 31, 2020 | 10.14 Mn |
| Jun 30, 2020 | 9.96 Mn |
| Dec 31, 2019 | 10.78 Mn |
| Jun 30, 2019 | 11.87 Mn |
| Dec 31, 2018 | 12.82 Mn |
| Jun 30, 2018 | 13.88 Mn |
| Jun 30, 2017 | 14.29 Mn |
| Mar 31, 2017 | 13.86 Mn |
| Jun 30, 2016 | 15.57 Mn |
| Jun 30, 2015 | 17.62 Mn |